Avacta Group Plc (AVCT) Earns “Corporate” Rating from FinnCap
Avacta Group Plc (LON:AVCT)‘s stock had its “corporate” rating reiterated by research analysts at FinnCap in a research report issued on Thursday. They presently have a GBX 200 ($2.59) price objective on the biotechnology company’s stock. FinnCap’s price target points to a potential upside of 164.90% from the stock’s previous close.
Avacta Group Plc (LON AVCT) remained flat at GBX 75.50 during mid-day trading on Thursday. 3,000 shares of the company traded hands. Avacta Group Plc has a 52 week low of GBX 60.00 and a 52 week high of GBX 103.95. The stock has a 50 day moving average price of GBX 81.20 and a 200 day moving average price of GBX 78.93. The company’s market capitalization is GBX 51.63 million.
TRADEMARK VIOLATION WARNING: “Avacta Group Plc (AVCT) Earns “Corporate” Rating from FinnCap” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/28/avacta-group-plc-avct-earns-corporate-rating-from-finncap.html.
In other news, insider Alastair Smith bought 33,225 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average cost of GBX 75 ($0.97) per share, with a total value of £24,918.75 ($32,228.08). Also, insider Michael Scott Albin bought 4,345 shares of the firm’s stock in a transaction that occurred on Tuesday, July 4th. The stock was purchased at an average cost of GBX 86 ($1.11) per share, for a total transaction of £3,736.70 ($4,832.77).
About Avacta Group Plc
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.